Protocol Ledger

NCT05624996 · Phase III · RECRUITING

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Interventional Phase III clinical trial protocol NCT05624996 sponsored by NRG Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-07-12 Enrollment: 474 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05624996
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)474 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05624996
Protocol FieldVerified Registry Value
NCT IdentifierNCT05624996
Consolidated Lead SponsorNRG Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment474 participants (ESTIMATED)
Registered Start Date2023-07-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI